-
1 week ago | 
yicaiglobal.com | Lin Zhiyin
(Yicai) May 30 -- As Hong Kong and Shanghai’s biopharmaceutical ecosystems become increasingly intertwined, Shanghai is looking to leverage Hong Kong as a “super-connector” to help local drugmakers break into global markets, according to a Shanghai government official overseeing the development of the biomedical industry.
-
2 weeks ago | 
yicaiglobal.com | Lin Zhiyin
(Yicai) May 23 -- Shares of Chinese drugmaker Hengrui Pharmaceutical soared nearly 30 percent on their first day of trading on the Hong Kong Stock Exchange. The stock [HKG: 1276] closed 25 percent up at HKD55.05 (USD7.03), giving the Jiangsu province-based firm a market capitalization of HKD365.5 billion (USD46.7 billion). Hengrui’s Shanghai-listed shares [SHA: 600276] fell 1.6 percent to CNY54.50 (USD7.57) today.
-
2 weeks ago | 
yicaiglobal.com | Lin Zhiyin
(Yicai) May 21 -- The number of pharmacies in China dropped in the fourth quarter of last year, with drugstores struggling due to the rapid growth of healthcare e-commerce. Some 14,100 brick-and-mortar pharmacies closed in China in the three months ended Dec. 31, while only 10,700 opened, according to figures from health industry data and consulting service platform Zhongkang CMH. Their total number fell 0.5 percent from a quarter earlier.
-
3 weeks ago | 
yicaiglobal.com | Ma Xiaohua |Lin Zhiyin |Wu Simin
(Yicai) May 16 -- If the United States and China are forced to decouple in the pharmaceutical sector, this could push up US drugmakers’ costs by half, industry insiders said, in response to a recent statement by the US Treasury Secretary that although the US does not seek a full break from China, it does want to bring key industries like pharmaceuticals back to US soil.
-
3 weeks ago | 
yicaiglobal.com | Lin Zhiyin
(Yicai) May 15 -- Hillhouse Group has sold HKD2.08 billion (USD266 million) worth of BeiGene’s Hong Kong-listed shares, capitalizing further on a substantial rally in the biopharmaceutical giant’s stock price this year. Soon after the sale, the Chinese private equity giant showed up as a cornerstone investor in drugmaker Hengrui Pharmaceuticals’ upcoming secondary listing in Hong Kong, Yicai learned.
-
3 weeks ago | 
yicaiglobal.com | Lin Zhiyin
(Yicai) May 14 -- InnoCare Pharma posted a profit in the first quarter of this year for the first time, mainly thanks to a surge in sales of the Chinese firm's core leukemia drug. Net profit was CNY18 million (USD2.5 million) in the three months ended March 31, compared with a net loss of CNY142.4 million (USD19.7 million) a year earlier, according to the Beijing-based firm's financial report released late yesterday. Revenue surged 130 percent to CNY381.3 million (USD52.8 million).
-
3 weeks ago | 
yicaiglobal.com | Wu Ziye |Tong Xin |Chen Shanshan |Lin Zhiyin
We sent you a codeEnter it below to verify via You'll need a passwordMake sure it's 8 characters or moreSHOW PASSWORD/HIDE PASSWORDSuccess! Welcome to Yicai GlobalFind your Yicai Global accountCheck your emailWe've sent an email to with a confirmation code. Enter the code below to reset your password. If you don't see the email, check your junk, spam or other folders. Change your passwordStrong passwords include numbers,letters,and special characters.
-
3 weeks ago | 
yicaiglobal.com | Lin Zhiyin
(Yicai) May 13 -- Guangzhou has published the initial results of its initiative to build a trusted data-sharing platform for the healthcare sector, as the major southern Chinese city works to open up the flow of medical data in order to speed up of the development of new technologies, drugs and medical devices through greater access to health information.
-
3 weeks ago | 
yicaiglobal.com | Lin Zhiyin
(Yicai) May 12 -- The share price of Beigene and several other Chinese pharmaceutical firms that have drugs approved for sale in the US took a knock today after US President Donald Trump announced plans to drastically cut prescription drug prices in the United States. Beigene’s share price [SHA: 688235] closed down 9 percent at CNY221.50 (USD30.71), while its Hong Kong-listed shares [HKG: 6160] slumped 9 percent to end the day at HKD127.80 (USD16.40). Other Chinese pharma firms were also affected.
-
1 month ago | 
yicaiglobal.com | Lin Zhiyin
(Yicai) May 8 -- Chinese biopharmaceutical giant BeiGene has reported its first-ever quarterly profit under US Generally Accepted Accounting Principles thanks to robust worldwide sales of its two core cancer drugs and tighter cost controls. Beigene raked in GAAP net profit of USD1.27 million in the first quarter, according to the Beijing-based firm’s latest earnings report.
